Temitope Ibukunoluwa Adegbenro

Temitope Ibukunoluwa Adegbenro

Auto-generated profile, based on publicly available information

Temitope Ibukunoluwa Adegbenro

University of Lagos Faculty of Pharmacy Lagos

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in Journal of Computational Biophysics and Chemistry
Verified
Journal Article
Closed access
DBDamilola Samuel Bodun
Damilola Samuel Bodun
AAAdeniyi Ayinde Abdulwahab
Adeniyi Ayinde Abdulwahab
TATemitope Ibukunoluwa Adegbenro
Temitope Ibukunoluwa Adegbenro
ECEmidun Olayinka Chidinma
Emidun Olayinka Chidinma
SOSamuel Aduramurewa Osunnaya
Samuel Aduramurewa Osunnaya
RARachael Oluwakamiye Abolade
Rachael Oluwakamiye Abolade

12 November 2025 in Biology Methods and Protocols
Verified
Journal Article
Open access
SDSuleiman Danladi
Suleiman Danladi
AAAyinde Abdulwahab Adeniyi
Ayinde Abdulwahab Adeniyi
ZSZainab Iman Sani
Zainab Iman Sani
ATAdegbenro Temitope
Adegbenro Temitope
HIV is a global public health challenge. The Reverse Transcriptase (RT) enzyme facilitates an important step in HIV replication. Inhibition of this enzyme provides a critical target for HIV treatment. The aim of this study is to employ computational techniques to screen bioactive compounds from different medicinal plants towards identifying potent HIV-1 RT inhibitors better activity than the current ones. We conducted a literature review of HIV-1 RT inhibitors, and eighty-four (84) compounds, while target receptor (1REV) was retrieved from Protein Data Bank. The molecular docking and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) evaluations were performed using the Maestro Schrodinger software user interface. The drug-likeness and pharmacokinetic profile evaluation were carried out using SwissADME and ADMETlab3.0 web servers. Lastly, molecular dynamics simulation study was conducted using the Desmond tool of Schrodinger. The molecular docking study revealed that Rosmarinic acid (-13.265 kcal/mol), Evafirenz/standard drug (-12.175 kcal/mol), Arctigenin (-11.322 kcal/mol), Luteolin (-11.274 kcal/mol), Anolignan A (-11.157 kcal/mol) and Quercetin (-11.129 kcal/mol) can effectively bind with high affinity and low energy values to the HIV-1 RT enzyme. The relative binding free energies of Rosmarinic acid, Evafirenz, Arctigenin, Luteolin, Anolignan A, and Quercetin were -66.85, -66.53, -51.83, -49.77, -58.17, and -49.62 Δg bind, respectively. The ADMET profile of Arctigenin was similar to that of Efavirenz, and better than that of other top compounds. The molecular dynamics simulation study showed better stability of rosmarinic acid with the active site of HIV-1 NNRT than the cocrystalized ligand. Out of the top five compounds identified in this study, Rosmarinic acid, a current inhibitor of HIV-1 RT in vitro, showed the most promising prediction. However, further in vivo studies and human clinical trials are required to provide more concrete information regarding its efficacy as potent HIV-1 RT inhibitors.

1 January 2025 in Journal of Global Health Science
Verified
Journal Article
Open access
PDF file
EOEjovwovwokeoghene Joseph Omohwovo
Ejovwovwokeoghene Joseph Omohwovo
JOJeremiah Oluwamayowa Omojuyigbe
Jeremiah Oluwamayowa Omojuyigbe
TATemitope Ibukunoluwa Adegbenro
Temitope Ibukunoluwa Adegbenro
SESomtochukwu Marycynthia Ezema
Somtochukwu Marycynthia Ezema
COChiwenite Kingsley Onyekwelu
Chiwenite Kingsley Onyekwelu
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Omohwovo EJ, et al. J Glob Health Sci. 2025 May;7:e5. https://doi.org/10.35500/jghs.2025.7.e5

20 January 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
DBDamilola Bodun
Damilola Bodun
IIISIAKA IBRAHIM
ISIAKA IBRAHIM
MBMUJEEBAT BASHIRU
MUJEEBAT BASHIRU
RARachael Oluwakamiye Abolade
Rachael Oluwakamiye Abolade
WNWilberforce K. Ndarawit
Wilberforce K. Ndarawit
OAOlayinka O. Ajani
Olayinka O. Ajani
Breast cancer, the most commonly diagnosed disease worldwide, has been linked to the overexpression of the kinesin Eg5 protein, a spindle motor protein crucial for the assembly and maintenance of the bipolar spindle during mitosis. This makes Eg5 an attractive therapeutic target for tumor treatment. To address the urgent need for effective treatments for this life-threatening illness, we utilized generative AI to design novel and potential inhibitors of this protein. In this study, a generative LSTM model was pretrained on SMILES data from ChEMBL and subsequently fine-tuned using SMILES of compounds with reported activity against the Eg5 protein. The fine-tuned model generated valid compounds, which were screened using a machine learning model, drug-likeness filters, molecular docking, and molecular dynamics (MD) simulations conducted over 200 ns. Five novel compounds with better binding affinities to Eg5 compared to the co-crystallized ligand were identified. The top compound, Compound 103 (a bioisostere of the co-crystallized ligand), demonstrated a significantly improved binding free energy (-82.68 kcal/mol) compared to the co-crystallized ligand (-76.98 kcal/mol), as determined by MM-GBSA calculations. ADMET predictions and MD simulations further confirmed that the top compounds interacted effectively with the target protein and exhibited drug-like properties. This study shows the potential of generative AI to explore our vast chemical space and find promising drug candidates. However, further in vitro and in vivo studies are needed to confirm the predicted biological effects of the top compounds.

17 December 2025 in ChemistrySelect
Verified
Journal Article
Closed access
DBDamilola Samuel Bodun
Damilola Samuel Bodun
RARachael Oluwakamiye Abolade
Rachael Oluwakamiye Abolade
CNChimezie Finian Nwadinigwe
Chimezie Finian Nwadinigwe
MBMujeebat Bashiru
Mujeebat Bashiru
MAMoyosoore Mopelola Adegbaju
Moyosoore Mopelola Adegbaju
EOEmmanuel Sunday Omirin
Emmanuel Sunday Omirin